160 related articles for article (PubMed ID: 26604187)
1. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database.
Saliba L; Moulis G; Abou Taam M; Rousseau V; Chebane L; Petitpain N; Baldin B; Pugnet G; Montastruc JL; Bagheri H
Fundam Clin Pharmacol; 2016 Apr; 30(2):162-71. PubMed ID: 26604187
[TBL] [Abstract][Full Text] [Related]
2. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
[TBL] [Abstract][Full Text] [Related]
3. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
4. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.
Moulis G; Sommet A; Lapeyre-Mestre M; Montastruc JL;
Rheumatology (Oxford); 2014 Oct; 53(10):1864-71. PubMed ID: 24899660
[TBL] [Abstract][Full Text] [Related]
5. TNF-α inhibitor-induced psoriasis: A decade of experience at the Cleveland Clinic.
Mazloom SE; Yan D; Hu JZ; Ya J; Husni ME; Warren CB; Fernandez AP
J Am Acad Dermatol; 2020 Dec; 83(6):1590-1598. PubMed ID: 30576759
[TBL] [Abstract][Full Text] [Related]
6. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
7. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis.
Gulyas K; Bodnar N; Nagy Z; Szamosi S; Horvath A; Vancsa A; Vegh E; Szabo Z; Szucs G; Szekanecz Z; Szanto S
Eur J Health Econ; 2014 May; 15 Suppl 1():S93-100. PubMed ID: 24832840
[TBL] [Abstract][Full Text] [Related]
8. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
[TBL] [Abstract][Full Text] [Related]
9. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
Kopp TI; Delcoigne B; Arkema EV; Jacobsen RK; Magyari M; Ibfelt EH; Locht H; Sellebjerg F; Cordtz RL; Jensen DV; Askling J; Dreyer L
Ann Rheum Dis; 2020 May; 79(5):566-572. PubMed ID: 32161058
[TBL] [Abstract][Full Text] [Related]
10. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
[TBL] [Abstract][Full Text] [Related]
11. TNF-α Inhibitors Decrease Classical CD14
Batko B; Schramm-Luc A; Skiba DS; Mikolajczyk TP; Siedlinski M
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30642076
[TBL] [Abstract][Full Text] [Related]
12. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study.
Thein D; Egeberg A; Skov L; Loft N
JAMA Dermatol; 2022 Sep; 158(9):997-1004. PubMed ID: 35767240
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor Necrosis Factor-Alpha Therapy and Hypoglycemia: A Real-World Pharmacovigilance Analysis.
Zhou Y; Xie W; Wang L; Zhu X; Li J; Liu L; Zhu S; Wang L
Drug Saf; 2022 Sep; 45(9):951-959. PubMed ID: 35857191
[TBL] [Abstract][Full Text] [Related]
14. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
McKenna MR; Stobaugh DJ; Deepak P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
[TBL] [Abstract][Full Text] [Related]
15. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
16. Risk of Serious Bacterial Infection Associated With Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Inflammatory Bowel Disease.
Lee WJ; Lee TA; Calip GS; Suda KJ; Briars L; Schumock GT
Inflamm Bowel Dis; 2018 Mar; 24(4):883-891. PubMed ID: 29562275
[TBL] [Abstract][Full Text] [Related]
17. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
18. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
19. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.
Dernoncourt A; Schmidt J; Duhaut P; Liabeuf S; Gras-Champel V; Masmoudi K; Bennis Y; Batteux B
Fundam Clin Pharmacol; 2022 Feb; 36(1):199-209. PubMed ID: 33973280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
